The Panic-Proof Portfolio (Stockchase Research)
Vertex Pharmaceuticals Inc.
VRTX-Q
PAST TOP PICK
Nov 16, 2023
(A Top Pick Jan 04/22, Up 57.9%)Stochchase Research Editor: Michael O'Reilly
Our PAST TOP PICK with VRTX has triggered its stop at $350. To remain disciplined, we recommend covering the position at this time. This will result in a net investment gain of 44%, when combined with our previous recommendations.
It's doing well, hitting new highs today. It's further along in its life cycle. Has a fine cystic fibrosis franchise. Shares are strong momentum, so he's staying in.
He likes it for developing non-addictive painkillers with potential FDA approvals ahead. They reported a great quarter a day before the election, but has since pulled back hard that baffles him. Looks like profit-taking in a stock that's jumped 113% since end-2021.
She trimmed it because it's up 20% this year because of the launch of their pain medicine. Tonight's earnings will be fine and their pipeline makes it a good stock long term.
He sold part of this. In Q1, the FDA approved a record low number of drugs, and Vertex has some important trials. Was nervous in a macro standpoint, but company fundamentals and valuation were reasonable. He hopes for a bounce.
Sold it. Long term this is great. He wrote a $19.50 covered call last Monday. Earnings slightly miss and the stock sold off. So, he hedged half the decline then got stopped out. It's pure risk management.
Our PAST TOP PICK with VRTX has triggered its stop at $350. To remain disciplined, we recommend covering the position at this time. This will result in a net investment gain of 44%, when combined with our previous recommendations.